Alphatec Holdings, Inc. ATEC

Healthcare SIC 3841 - Surgical & Medical Instruments & Apparatus NAICS Manufacturing › Miscellaneous Manufacturing › Medical Equipment and Supplies Manufacturing › Surgical and Medical Instrument Manufacturing derived Nasdaq

We are a medical technology company, headquartered in Carlsbad, California, focused on the design, development, and advancement of technology for better surgical treatment of spine disorders. By applying our unique, 100% spine focus and deep industry know-how, we aim to revolutionize spine surgery through clinical distinction. The sophisticated approaches that we create from the ground up integrate with our expanding InformatiX™ ("IX") platform to objectively inform surgery and achieve the goals of spine surgery more predictably and more reproducibly. We have a comprehensive product portfolio designed to address the spine's various pathologies and we are perpetually innovating to accomplish our vision to be the standard bearer in spine.

Last close 11.11 2026-10-23
Market cap $1.72B 2026-06-30 share count
52-week range 6.82 - 23.29

Valuation FY2025 figures against the last close

P/S2.2x
P/E—
P/FCF618.1x
EV/EBITDA—
Dividend yield—
Diluted EPS-0.96

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $764.2M$611.6M$482.3M$350.9M$243.2M$144.9M$113.4M$91.7M$101.7M$120.2M
Cost of revenue $232.3M$187.3M$172.1M$117.8M$85.5M$42.4M$35.8M$28.5M$33.5M$44.1M
Gross profit $531.9M$424.3M$310.2M$233.1M$157.8M$102.5M$77.6M$63.2M$68.2M$76.1M
SG&A $498.5M$450.2M$374.1M$300.0M$229.3M$129.2M$101.7M$72.6M$70.0M$26.3M
Total operating expenses $614.0M$560.4M$483.6M$380.0M$285.8M$161.4M$124.9M$85.7M$77.2M$91.5M
Operating income -$82.1M-$136.2M-$173.4M-$147.0M-$128.1M-$58.9M-$47.3M-$22.4M-$9.0M-$15.4M
Interest expense $45.9M$24.9M$16.6M$5.5M$7.1M$12.4M$9.9M——$5.4M
Pre-tax income -$143.4M-$162.1M-$186.9M-$152.0M-$144.2M-$78.8M-$57.1M-$30.2M-$4.6M-$30.9M
Income tax $45.0K$50.0K$277.0K$716.0K$1.1M$145.0K$239.0K$1.4M$34.0K$4.6M
Net income -$143.4M-$162.1M-$186.6M-$151.3M-$143.0M-$79.0M-$57.0M-$29.0M-$2.3M-$29.9M
EPS, basic -0.96-1.13-1.54-1.46-1.49-1.18—-1.20-0.18-3.49
EPS, diluted -0.96-1.13-1.54-1.46-1.49-1.18-1.09-1.20-1.08-3.49
Shares, diluted (wtd. avg.) 150.1M142.9M121.2M103.4M96.2M67.0M—35.3M13.3M8.6M

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $160.8M$138.8M$221.0M$84.7M$187.2M$107.8M$47.1M$29.1M$22.5M$19.6M
Receivables $97.3M$83.0M$72.6M$60.1M$41.9M$23.5M$16.1M$15.1M$14.8M$18.5M
Inventory $169.4M$175.3M$136.8M$101.5M$91.7M$46.0M$34.9M$28.8M$27.3M$30.1M
Total current assets $450.9M$417.4M$451.1M$255.6M$331.2M$184.2M$108.3M$75.5M$66.5M$72.8M
Property, plant and equipment $135.3M$156.4M$149.8M$102.0M$87.4M$36.7M$19.7M$13.2M$12.7M$15.1M
Goodwill $75.2M$71.0M$73.0M$47.4M$39.7M$13.9M$13.9M$13.9M—$0
Other intangibles $93.5M$93.5M$102.5M$82.8M$85.3M$24.7M$25.6M$26.4M$5.2M$5.7M
Total assets $791.2M$775.7M$805.2M$521.0M$572.1M$261.2M$169.9M$129.5M$84.7M$94.2M
Accounts payable $40.9M$53.0M$49.0M$34.7M$25.7M$17.6M$7.8M$4.4M$3.9M$8.7M
Short-term debt $64.5M$1.7M$1.8M$14.9M$342.0K$4.2M$489.0K$3.3M$3.3M$3.1M
Total current liabilities $219.2M$153.0M$157.6M$138.9M$101.1M$58.3M$36.4M$30.6M$29.7M$40.1M
Long-term debt $501.4M$574.5M$511.0M$349.5M$326.5M$38.0M$53.4M$42.3M$37.8M$43.1M
Retained earnings -$1.42B-$1.28B-$1.12B-$932.3M-$781.0M-$638.0M-$558.9M-$501.9M-$459.5M-$457.2M
Total equity $12.4M-$14.2M$78.1M-$34.7M$80.7M$129.9M$43.6M$17.6M-$26.7M-$41.5M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow $45.2M-$44.7M-$78.5M-$75.1M-$73.3M-$46.4M-$33.1M-$25.6M-$8.7M-$10.0M
Depreciation and amortisation $77.5M$78.4M$56.1M$41.2M$26.8M$10.9M$7.6M$6.8M$7.5M$12.4M
Stock-based compensation $73.7M$73.3M$81.2M$40.6M$36.5M$17.7M$11.0M$5.3M$4.0M$1.6M
Capital expenditure $42.5M$83.2M$80.5M$49.5M$68.5M$23.1M$13.0M$6.5M$7.6M$8.9M
Investing cash flow -$53.4M-$93.1M-$142.0M-$58.3M-$157.8M-$23.9M-$13.0M-$21.7M-$6.5M$62.0M
Financing cash flow $30.0M$56.2M$356.9M$31.2M$312.0M$130.8M$64.2M$53.9M$17.8M-$43.4M
Buybacks ————$25.0M—————

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-191867.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -250M 0 250M 500M 750M 1B Revenue, FY2016: 120.2M Gross profit, FY2016: 76.1M Net income, FY2016: -29.9M Revenue, FY2017: 101.7M Gross profit, FY2017: 68.2M Net income, FY2017: -2.3M Revenue, FY2018: 91.7M Gross profit, FY2018: 63.2M Net income, FY2018: -29M Revenue, FY2019: 113.4M Gross profit, FY2019: 77.6M Net income, FY2019: -57M Revenue, FY2020: 144.9M Gross profit, FY2020: 102.5M Net income, FY2020: -79M Revenue, FY2021: 243.2M Gross profit, FY2021: 157.8M Net income, FY2021: -143M Revenue, FY2022: 350.9M Gross profit, FY2022: 233.1M Net income, FY2022: -151.3M Revenue, FY2023: 482.3M Gross profit, FY2023: 310.2M Net income, FY2023: -186.6M Revenue, FY2024: 611.6M Gross profit, FY2024: 424.3M Net income, FY2024: -162.1M Revenue, FY2025: 764.2M Gross profit, FY2025: 531.9M Net income, FY2025: -143.4M FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue $120.2M $101.7M $91.7M $113.4M $144.9M $243.2M $350.9M $482.3M $611.6M $764.2M
Gross profit $76.1M $68.2M $63.2M $77.6M $102.5M $157.8M $233.1M $310.2M $424.3M $531.9M
Net income -$29.9M -$2.3M -$29.0M -$57.0M -$79.0M -$143.0M -$151.3M -$186.6M -$162.1M -$143.4M

Recent filings and events

  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
  • Material agreement terminated An agreement that mattered has ended. Often the other half of a deal that fell through. Item 1.02
  • Results announced Item 2.02
  • New debt or obligation The company has taken on debt or a comparable obligation. Item 2.03
  • Officer or director change Item 5.02
  • Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Results announced Item 2.02
  • Results announced Item 2.02

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 3841

TickerCompanyMarket capP/ERevenue growth
SYK STRYKER CORP $117.81B 36.6x 11.2%
MMM 3M CO $89.46B 28.9x 1.5%
BSX BOSTON SCIENTIFIC CORP $66.22B 23.6x 19.9%
BDX BECTON DICKINSON & CO $54.18B 34.2x 8.2%
RMD RESMED INC $36.48B 24.2x 9.9%
DXCM DEXCOM INC $29.41B 37.3x 15.6%
MDLN Medline Inc. $29.20B — 11.5%
WST WEST PHARMACEUTICAL SERVICES INC $27.60B 57.8x 6.3%